Avinger (AVGR) Competitors $0.47 0.00 (0.00%) As of 05/20/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVGR vs. LYRA, BLAC, CHEK, LUCY, NUWE, AMIX, GCTK, HSCS, QNRX, and VEROShould you be buying Avinger stock or one of its competitors? The main competitors of Avinger include Lyra Therapeutics (LYRA), Bellevue Life Sciences Acquisition (BLAC), Check-Cap (CHEK), Innovative Eyewear (LUCY), Nuwellis (NUWE), Autonomix Medical (AMIX), GlucoTrack (GCTK), Heart Test Laboratories (HSCS), Quoin Pharmaceuticals (QNRX), and Venus Concept (VERO). These companies are all part of the "medical equipment" industry. Avinger vs. Lyra Therapeutics Bellevue Life Sciences Acquisition Check-Cap Innovative Eyewear Nuwellis Autonomix Medical GlucoTrack Heart Test Laboratories Quoin Pharmaceuticals Venus Concept Avinger (NASDAQ:AVGR) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Do insiders & institutionals have more ownership in AVGR or LYRA? 18.3% of Avinger shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 42.8% of Avinger shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor AVGR or LYRA? Avinger received 369 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. However, 58.54% of users gave Lyra Therapeutics an outperform vote while only 55.67% of users gave Avinger an outperform vote. CompanyUnderperformOutperformAvingerOutperform Votes39355.67% Underperform Votes31344.33% Lyra TherapeuticsOutperform Votes2458.54% Underperform Votes1741.46% Which has higher earnings & valuation, AVGR or LYRA? Avinger has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Avinger, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvinger$7.26M0.22-$18.32M-$11.06-0.04Lyra Therapeutics$1.19M5.26-$62.68M-$1.21-0.08 Does the media refer more to AVGR or LYRA? In the previous week, Avinger had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for Avinger and 0 mentions for Lyra Therapeutics. Lyra Therapeutics' average media sentiment score of 0.00 beat Avinger's score of -0.55 indicating that Lyra Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Avinger Negative Lyra Therapeutics Neutral Which has more volatility and risk, AVGR or LYRA? Avinger has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500. Is AVGR or LYRA more profitable? Avinger has a net margin of -261.06% compared to Lyra Therapeutics' net margin of -6,635.76%. Lyra Therapeutics' return on equity of -125.07% beat Avinger's return on equity.Company Net Margins Return on Equity Return on Assets Avinger-261.06% -5,527.11% -123.25% Lyra Therapeutics -6,635.76%-125.07%-59.74% Do analysts prefer AVGR or LYRA? Lyra Therapeutics has a consensus price target of $2.00, indicating a potential upside of 2,027.66%. Given Lyra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lyra Therapeutics is more favorable than Avinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avinger 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lyra Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryLyra Therapeutics beats Avinger on 10 of the 18 factors compared between the two stocks. Get Avinger News Delivered to You Automatically Sign up to receive the latest news and ratings for AVGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVGR vs. The Competition Export to ExcelMetricAvingerSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.57M$4.50B$5.37B$8.39BDividend YieldN/A43.63%5.22%4.10%P/E Ratio-0.0429.4326.7719.71Price / Sales0.2267.72393.17117.39Price / CashN/A51.0838.2534.62Price / Book-0.106.236.794.50Net Income-$18.32M$68.16M$3.23B$248.18M7 Day PerformanceN/A-0.19%1.53%0.20%1 Month PerformanceN/A19.19%10.06%12.37%1 Year Performance-84.01%21.47%16.74%7.04% Avinger Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVGRAvingerN/A$0.47flatN/AN/A$1.57M$7.26M-0.0470Analyst ForecastLYRALyra Therapeutics2.0301 of 5 stars$0.09-4.1%$2.00+2,023.1%-73.6%$6.24M$1.53M-0.0650Gap UpBLACBellevue Life Sciences AcquisitionN/A$1.25-2.3%N/A-89.5%$5.05MN/A0.00N/ACHEKCheck-Cap0.4015 of 5 stars$0.82-0.5%N/A-60.2%$4.77MN/A-0.2780News CoverageAnalyst ForecastGap DownLUCYInnovative Eyewear0.3022 of 5 stars$1.87+2.2%N/A-33.3%$4.59M$1.64M-0.199Positive NewsNUWENuwellis2.5045 of 5 stars$0.99+0.1%$17.00+1,617.2%-90.1%$4.33M$8.74M-0.0170AMIXAutonomix Medical2.2788 of 5 stars$1.75-1.7%$16.50+842.9%-96.0%$4.31MN/A-0.141GCTKGlucoTrack0.9899 of 5 stars$0.15-4.1%N/A-99.7%$3.81MN/A0.005Positive NewsGap UpHSCSHeart Test Laboratories2.4015 of 5 stars$3.47+1.2%$13.00+274.6%-30.7%$3.75M$14,700.00-0.4410Positive NewsQNRXQuoin Pharmaceuticals0.347 of 5 stars$6.12-1.1%N/A-67.7%$3.60MN/A-1.514VEROVenus Concept0.8629 of 5 stars$2.49+2.5%N/A-66.7%$3.55M$64.83M-0.31410Earnings ReportGap Down Related Companies and Tools Related Companies Lyra Therapeutics Alternatives Bellevue Life Sciences Acquisition Alternatives Check-Cap Alternatives Innovative Eyewear Alternatives Nuwellis Alternatives Autonomix Medical Alternatives GlucoTrack Alternatives Heart Test Laboratories Alternatives Quoin Pharmaceuticals Alternatives Venus Concept Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVGR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avinger With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
